84 results about "Radioactive tracer" patented technology

The invention is suitable for the technical field of biological medicine and nuclear medicine, and provides a PD-L1 targeting compound, a radioactive tracer agent and a preparation method and application of the PD-L1 targeting compound and the radioactive tracer agent. The radioactive tracer provided by the invention has strong binding force with PD-L1, can accurately locate PD-L1 in vivo, has excellent in-vivo targeting performance, and can achieve the purpose of tumor molecular imaging through nuclear medicine imaging; meanwhile, noninvasive visualization of PD-L1 expression is achieved, non-invasive tumor diagnosis can be effectively completed through small animal PET / CT verification, and the clinical application prospect is wide; in addition, the PD-L1 targeting compound and the radioactive tracer derived from the PD-L1 targeting compound further have the advantages of being simple in preparation process, low in cost, high in specificity, good in in-vivo and in-vitro stability, long in imaging period, easy to clinically convert and the like, and the comprehensive performance is outstanding.

This application relates to the field of medical image processing technology, and provides a method, apparatus, device, and storage medium for reconstructing ECT images. This allows for more thorough capture of subtle changes in the concentration distribution of radioactive tracers at high temporal resolution, helping to reduce image noise levels and improve image quality. This application obtains a first ECT image sequence; the first ECT image sequence is obtained by scanning with an ECT scanning device; the first ECT image sequence is input into a pre-constructed intermediate frame prediction network to obtain an estimated second ECT image sequence; using the estimated second ECT image sequence as a priori image, a target second ECT image sequence is reconstructed; the estimated second ECT image sequence and the target second ECT image sequence belong to the second ECT image sequence; the temporal resolution of the second ECT image sequence is higher than that of the first ECT image sequence.

A precursor compound and a radioligand for cancer diagnosis and treatment comprises a high-affinity ligand PL for a cancer- associated protein conjugated to a covalent warhead CW for strong or covalent binding to an amino acid sidechain of the cancer-associated protein and a chelator Ch for complexation of a radioisotope or a leaving group LR for substitution with a radioisotope, wherein the covalent warhead CW is configured for quasi-covalent ionic binding using a sulfonic acid group or for covalent binding using a sulfur fluoride exchange (SuFEx) group, a benzotriazole or N-methyl-N- arylmethanesulfonamide leaving group or a malolactone group for strain-release alkylation.

The invention relates to a PD-L1 targeted biphenyl radioactive tracer and application thereof, and belongs to the technical field of PET imaging. The invention provides a series of PD-L1 targeted biphenyl radioactive tracers which comprise [18F] LG-2, [18F] LG-3, [18F] LG-13, [18F] LG-14, [18F] LG-15 and the like, the series of biphenyl radioactive tracers have good in-vitro stability, can be specifically combined with PD-L1, and are relatively good in targeting specificity, and therefore, the series of biphenyl radioactive tracers can be applied to the field of radioactive tracers. The series of biphenyl radioactive tracers can noninvasively, accurately, dynamically and systemically monitor the expression level and change of PD-L1 in tumors from the molecular level in real time through PET imaging, and then the curative effect of PD-1 / PD-L1 immunotherapy on tumor patients is effectively evaluated.

The invention belongs to the technical field of agricultural drip irrigation, and provides a method for monitoring water, fertilizer and growth vigor of crops by using C14 drip irrigation, which comprises the following steps of: after injecting a C14-containing radioactive tracer into a drip irrigation system, monitoring spatial distribution and migration of C14 in a drip irrigation zone, soil and crop tissues in real time, and performing gamma-ray imaging and soil profile detection by using an unmanned aerial vehicle to obtain the growth vigor of the crops. Obtaining multi-source data; fusing the data to construct a water and fertilizer migration-absorption model, analyzing the water and fertilizer utilization rate of a root zone, obtaining crop growth parameters in combination with a multispectral image, and dynamically generating a water and fertilizer optimization scheme; according to the scheme, the flow, the concentration and the irrigation time of the drip irrigation system are automatically adjusted, and the adjustment period is 12-24 hours; the C14 tracing mode is combined with the unmanned aerial vehicle imaging technology, water and fertilizer migration and utilization are comprehensively monitored in real time, the conduction path and usage amount of water and fertilizer in the root zone are accurately analyzed, dynamic optimization and closed-loop control of water and fertilizer management are achieved, and therefore the water and fertilizer utilization efficiency is improved, and crop yield improvement is promoted.

The invention discloses a medical image coincidence event processing method, system and device, equipment and a medium. The coincidence event processing method for the medical image comprises the steps that an original event is obtained, and the original event is an event composed of single photons and obtained by collecting photons generated by decay of a radioactive tracer through a detector; based on the energy information and the time information of the original events, the original events are discriminated, effective events are obtained, the effective events comprise true coincidence events and random coincidence events, and the true coincidence events are used for medical image reconstruction; determining a time window for the detector to collect photons, and dynamically adjusting the window width of the time window based on the change trend of the event counting rate; the valid events are processed based on the time window to reduce random coincidence events in the valid events.

The present invention discloses a preparation system for non-radioactive tracer ceramsite with stable signal-to-noise ratio, comprising: a tracer ceramsite green body preparation device, a detection unit, a control system, a database, and an adjustment and optimization module; a method for real-time online regulating the content of tracer elements contained in the tracer ceramsite based on the ζ o value is established, eliminating the phenomenon of low or high content of tracer elements caused by uneven mixing or other factors during the production process of the tracer ceramsite, and accurately controlling the content of tracer elements within the set threshold. According to the feedback of the measured data ζ 测 downhole, the set threshold ζ 阈 of the tracer ceramsite is adjusted in real time. With the linkage between the wellhead and the downhole, stable signal-to-noise ratio can be achieved when monitoring the fracture information by the neutron activation prompt gamma ray method of the in-use tracer ceramsite in a complex fracturing environment, and the sudden increase and decrease of the captured gamma signal during fracture logging such as different logging tool parameters, wellbore environment, and oil and gas reservoirs can be avoided, thereby improving the logging success rate.

The invention relates to a compound of general formula I wherein A is an amino acid selected from the group consisting of wherein the amino acids are optionally substituted: k is 0, 1, or 2 independently at each occurrence; m is 1, 2, 3, 4 or 5 independently at each occurrence; n is 0, 1, 2 or 3 independently at each occurrence; p is 1, 2 or 3 independently at each occurrence; q is 1, 2 or 3 independently at each occurrence; X and Y are substituted or unsubstituted amino acids; Z is selected from the group consisting of where v is 0, 1 or 2; G 1 N or CR a is; G 2 N or CR b is; G 3 N or CR c is; G 4 N or CR d is; where 0, 1 or 2 of G 1 , G2 , G 3 and G 4 N is / are; R a , R b , R c and, if present, are in each case independently selected from the group consisting of hydrogen, halogen, hydroxy, carboxyl, C 1 -C 6 -Alkyl, C 1 -C 6 -Alkoxy, cyano, nitro and Si(tBu) 2 F exists, provided that only 1 or 2 of R a , R b , R c and R d Halogen is / are; and R is selected from the group consisting of hydrogen, halogen, hydroxy, C 1 -C 6 -alkyl and C 1 -C 6 -alkoxy.

The present invention relates to the technical field of molecular imaging probes, and particularly relates to a molecular imaging probe labeling precursor targeting the DDR1 receptor, a probe thereof, and a preparation method and application thereof. The molecular imaging probe labeling precursor targeting the DDR1 receptor provided by the present invention reacts with a radionuclide to generate a molecular imaging probe targeting the DDR1 receptor, which has a strong receptor binding force with the DDR1 receptor, can accurately locate the DDR1 receptor in vivo, has excellent in vivo targeting performance, and realizes the purpose of tumor molecular imaging through nuclear medicine imaging. Compared with the radioactive tracer [68Ga]Ga-SDUHYX01, the molecular imaging probe [68Ga]Ga-SDUHYX04 optimizes the molecular structure, reduces the lipophilicity, adjusts the metabolic pathway of the molecular imaging probe, thereby making the tumor-to-liver ratio of the molecular imaging probe higher, and also showing excellent imaging effects at 60 minutes.

The invention relates to a compound of general formula I wherein A is an amino acid selected from the group consisting of wherein the amino acids are optionally substituted: k is 0, 1, or 2 independently at each occurrence; m is 1, 2, 3, 4 or 5 independently at each occurrence; n is 0, 1, 2 or 3 independently at each occurrence; p is 1, 2 or 3 independently at each occurrence; q is 1, 2 or 3 independently at each occurrence; X and Y are substituted or unsubstituted amino acids; Z is selected from the group consisting of where v is 0, 1 or 2; G1 N or CR a is; G2 N or CR b is; G3 N or CR c is; G4 N or CR a is; where 0, 1 or 2 of G1, G2, G3 and G4 is / are N; R a , R b , Rc and R d , if present, are in each case independently selected from the group consisting of hydrogen, halogen, hydroxy, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, cyano, nitro and Si(tBu)2F, provided that only 1 or 2 of R a , R b , R c and R d Halogen is / are; and R is selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl and C1-C6 alkoxy.

A method for performing dynamic positron emission tomography (PET) is disclosed. The method includes collecting volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals, capturing a magnetic resonance image of the target site, and performing a motion correction process to the volumetric radioactive measurement data to produce motion corrected PET data. The method further includes co-registering the magnetic resonance image and motion corrected data to generate a co-registered dynamic PET volume, and applying a model corrected input function (MCIF) to the co-registered dynamic PET volume to calibrate an uptake amount of the radioactive tracer in the target site.

The present disclosure relates to [18F]-labeled imidazopyridine derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in in vivo diagnosis, preclinical and clinical imaging, patient stratification on the basis of mutational status of c-abl and assessing response to therapeutic treatments. The present disclosure furtherrelates to the use of [18F]-labeled imidazopyridine derivatives as PET radiotracers. Thedisclosure also provides a process for the radiosynthesis of [18F]-labeled imidazopyridinederivatives.

A radiotracer injection system for safe use in industrial plants allows for rapid coupling of the radiotracer element storage bottle. The entire set is fully pneumatically driven and allows radiotracer injection in the form of a rapid pulse or step pulse. The injector system can be used with radiotracers in liquid (aqueous or oil) and gaseous form. The system is a sealed and safe unit to work in systems with internal pressure up to 300 Bar. This prevents the need to handle radioactive material in industrial plants, as the radiotracer used in each injection is already delivered inside its respective bottle. Quick-coupling connections allow quick and safe exchange of a used bottle for one with a new radiotracer, without having to disconnect the injector from the system. The injection machine has cylindrical symmetry, which allows the use of shielding with prismatic lead bricks, forming a protective castle around the unit.

DAZTA 5 -A radioisotope named PPA2 68 Ga and 177 Novel precursors for PET / CT diagnosis and nuclear therapy of SSR-active lesions using Lu improve affinity, specificity, and imaging of small metastases.

The present invention relates to a ligand-SIF A-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

The invention relates to a PARP (poly ADP-ribose polymerase)-targeted single-photon tracer, a labeling precursor thereof, a preparation method and application, the tracer takes Olaparib as a lead compound, develops HYNIC-Olaparib, and adopts hydrophilic triglycine and EDDA as auxiliary ligands to successfully prepare the PARP-targeted single-photon tracer with high stability and purity (gt; the < 99mTc >-labeled PARP-targeting tracer agent with the molecular weight of 9mTc (9mTc, 90%) has good hydrophilicity, effectively reduces radiation accumulation in the abdominal cavity, can specifically target PARP-1 in MDA-MB-453 cells, clearly displays the MDA-MB-453 tumor focus through Micro SPECT / CT imaging, has obvious tumor / background contrast, can be efficiently removed from non-target organs, and has huge potential of becoming a novel PARP imaging radioactive tracer agent.

The invention belongs to the technical field of nuclear medicine imaging, and discloses a radioactive tracer agent distribution quantification optimization method and related equipment, and the method comprises the steps: obtaining scanning bed deformation information, moving track information and physiological motion dynamic information of a patient, and obtaining a radioactive tracer agent distribution quantification optimization result based on the scanning bed deformation information, the moving track information and the physiological motion dynamic information; the method comprises the steps of constructing a multi-source error integrated influence model, performing radioactive tracer distribution reconstruction on original detection data through an OSEM algorithm based on the multi-source error integrated influence model to obtain real distribution information of a radioactive tracer, and performing calculation according to the real distribution information to obtain a standardized uptake value. By means of the method, the accuracy of the radioactive tracer agent distribution quantification result is improved.

The present invention relates to the fields of medicinal chemistry, radiopharmaceutical chemistry, and clinical nuclear medicine, and in particular to a compound targeting CDK4 / 6 and a radioactive tracer derived therefrom. The CDK4 / 6-targeting compound has the structures shown in the following formulas (I) and (II). The radioactive tracer provided by the present invention has strong binding affinity with CDK4 / 6, can accurately locate CDK4 / 6 in vivo, exhibits excellent in vivo targeting performance, and achieves tumor molecular imaging through nuclear medicine imaging. Formula (I); Formula (II).

The present invention discloses an optimized method for evaluating the effects of a satiety and stomach-occupying capsule through multi-dimensional monitoring, which relates to the technical field of evaluation and optimization. It includes collecting the scores of stomach-occupying capsule takers on satiety, analyzing through curves, and calculating the satiety change rate of the takers; obtaining the concentration of the radioactive tracer in the stomach based on the gastric emptying curve model according to the gastric emptying process, and calculating the gastric emptying time of the radioactive tracer based on the concentration of the radioactive tracer; analyzing the short-term effects after taking the stomach-occupying capsule through the satiety change rate and the gastric emptying time; analyzing the long-term effects after taking the stomach-occupying capsule according to the change in food intake and the weight change rate; judging whether the process of taking the stomach-occupying capsule needs to be optimized based on fuzzy inference, and generating a personalized optimization plan. Through multi-dimensional data monitoring, the present invention can comprehensively evaluate the use effects of the stomach-occupying capsule, rather than relying solely on single subjective feedback, increasing the accuracy and comprehensiveness of the evaluation.

A method for evaluating induced fractures in a wellbore includes obtaining a first set of data in a wellbore using a downhole tool. The method also includes pumping a first proppant into the wellbore after the first set of data is obtained. The first proppant includes a first tracer that is not radioactive. The method also includes pumping a second proppant into the wellbore. The second proppant includes a second tracer that is not radioactive. The second tracer is different than the first tracer. The first proppant and the second proppant flow into fractures in the wellbore. The method also includes obtaining a second set of data in the wellbore using the downhole tool after the first and second proppants are pumped into the wellbore. The method also includes comparing the first and second sets of data.

The present disclosure relates to compounds of Formula (1a), (1b), (1c) or (1d) and pharmaceutically acceptable salts thereof, wherein X, Z, L, CM and R1 are defined herein, and their use as cancer diagnostic or imaging agents.

The invention relates to the technical field of molecular imaging probes, in particular to a molecular imaging probe labeling precursor of a targeted DDR1 receptor, a probe and a preparation method and application of the molecular imaging probe labeling precursor. The molecular imaging probe of the targeted DDR1 receptor, which is generated by reaction of the marker precursor of the molecular imaging probe of the targeted DDR1 receptor and radionuclide, has relatively strong receptor binding force with the DDR1 receptor, can accurately position the DDR1 receptor in vivo, has excellent in-vivo targeting performance, and achieves the purpose of tumor molecular imaging through nuclear medicine imaging. Compared with a radioactive tracer agent [68Ga] Ga-SDUHYX01, the molecular imaging probe [68Ga] Ga-SDUHYX04 has the advantages that the lipophilicity is reduced and the metabolic pathway of the molecular imaging probe is adjusted by optimizing the molecular structure, so that the tumor liver ratio of the molecular imaging probe is higher, and meanwhile, the molecular imaging probe can also show an excellent imaging effect within 60 minutes.

The application discloses a radioactive separation laboratory environment radiation field dynamic modeling method and system, and belongs to the field of chemical process modeling. Step 1, the concentration distribution of a non-radioactive process tracer physically associated with a target radionuclide in a process fluid is obtained; step 2, based on the concentration distribution and the macroscopic residence time distribution of the material, the pre-judgment source term of the radionuclide is obtained through time translation and decay scaling; step 3, the radiation field observation waveform collected by a heterogeneous radiation sensitive field sensor network and independent of the pre-judgment source term is obtained; step 4, the theoretical radiation field change waveform calculated based on the pre-judgment source term is obtained; the application can obtain the concentration distribution of the non-radioactive tracer physically associated with the target radionuclide, eliminate the inherent bias of the source term from the source, and accurately depict the time-varying characteristics of the source term caused by the continuous migration of the material without making steady-state or quasi-static simplification assumptions on fluid turbulence, two-phase interface dynamic change and other processes.

The invention belongs to the technical field of pharmaceutical chemicals, and provides a dopamine D3 receptor radioactive tracer and a preparation method and application thereof. According to the dopamine D3 receptor radiotracer (11C-YQA14) disclosed by the invention, a structure as shown in a formula 1 is used as a precursor compound, and gaseous 11C-CH3I is introduced under a closed condition to obtain the 11C-YQA14. The dopamine D3 receptor radioactive tracer has ideal affinity to a dopamine D3 receptor and has low affinity to a dopamine D2 receptor, so that the dopamine D3 receptor radioactive tracer can selectively recognize the dopamine D3 receptor and has low recognizability to the dopamine D2 receptor.

A fluorine-18-labeled positron emission tomography (PET) radiotracer for diagnosing neuroinflammation, stroke or cerebral infarction and a method for using the radiotracer are provided.

The present invention relates to the field of biomedical technologies, and particularly relates to a polypeptide targeting TREM-1 protein and a radioisotope tracer derived therefrom. The present invention provides a polypeptide NOTA-C-IPB-YIT targeting TREM-1 positive tumors, which is labeled with <supgt;68< / supgt;Ga to construct a radioisotope tracer [<supgt;68< / supgt;Ga]Ga-NOTA-C-IPB-YIT targeting TREM-1 protein. Through in vitro radiochemical property studies and in vivo stability studies, it is found that the radioisotope tracer [<supgt;68< / supgt;Ga]Ga-NOTA-C-IPB-YIT has strong stability and is hydrophilic; through cell uptake studies and receptor binding studies, it is found that the radioisotope tracer [<supgt;68< / supgt;Ga]Ga-NOTA-C-IPB-YIT has good affinity for the TREM-1 protein expressed by U87MG cells; by investigating the tumor imaging effect of the radioisotope tracer [<supgt;68< / supgt;Ga]Ga-NOTA-C-IPB-YIT with a small animal PET / CT, it is found that the radioisotope tracer [<supgt;68< / supgt;Ga]Ga-NOTA-C-IPB-YIT can be used for in vivo imaging of TREM-1 positive tumors.

Provided are a precursor compound and a radioactive tracer for targeting fibroblast activation protein. This precursor compound and radioactive tracer have a chelating agent (Ch) and a ligand (TV). Their respective structures are as follows. [Chemical Formula 1] JPEG2025521837000035.jpg108169

The invention provides a low-dose PET image denoising method and system based on prompt learning and line integral projection constraint. The method comprises the following steps: constructing a PET image denoising model fused with a magnetic resonance multi-mode prompt learning mechanism; constructing a multi-domain loss function with physical consistency constraints; constructing a pairing training data set of a low-dose PET image, a standard-dose PET image and an MR image spatially corresponding to the PET image, and performing end-to-end training on the PET image denoising model by using the multi-domain loss function; and taking the acquired low-dose PET image and the MR image corresponding to the low-dose PET image as input, and carrying out denoising recovery on the low-dose PET image by utilizing the trained PET image denoising model to obtain a denoised PET image. According to the invention, on the premise of reducing the dosage of the radioactive tracer agent, the structural accuracy and the physical interpretability of the PET image are effectively improved, and a solution with high efficiency, low risk and high reliability is provided for clinical low-dosage PET examination.

A precursor compound for a therapeutic, FAP-targeted radioligand comprises an FAP ligand that contains a covalent warhead.

Systems, methods, and devices provide data correction for positron emission tomography (PET) examinations using an external, supplemental radioactive source. The supplemental radioactive source is formed of a uniformly distributed radionuclide. The uniformly distributed radionuclide is positioned in a support structure which is positioned into an inner bore of a PET scanner and secured in place by a friction fit, or directly integrated into the PET system. A transmission source control system moves the one or more 2024 / 059537 transmission sources into the support structure for performing the PET examination (e.g., using a hydraulic system). The transmission source control system also retracts the one or more transmission sources back into a source storage device upon completing the PET examination. Various data correction algorithms use the first PET signal data, originating from a radiotracer injected in the patient, and second PET signal data, originating from the uniformly distributed radionuclide.